Publication date: Oct 14, 2024
Immune checkpoint blockade (ICB) is a promising cancer therapy; however, resistance frequently develops. To explore ICB resistance mechanisms, we develop Immunotherapy Resistance cell-cell Interaction Scanner (IRIS), a machine learning model aimed at identifying cell-type-specific tumor microenvironment ligand-receptor interactions relevant to ICB resistance. Applying IRIS to deconvolved transcriptomics data of the five largest melanoma ICB cohorts, we identify specific downregulated interactions, termed resistance downregulated interactions (RDI), as tumors develop resistance. These RDIs often involve chemokine signaling and offer a stronger predictive signal for ICB response compared to upregulated interactions or the state-of-the-art published transcriptomics biomarkers. Validation across multiple independent melanoma patient cohorts and modalities confirms that RDI activity is associated with CD8 + T cell infiltration and highly manifested in hot/brisk tumors. This study presents a strongly predictive ICB response biomarker, highlighting the key role of downregulating chemotaxis-associated ligand-receptor interactions in inhibiting lymphocyte infiltration in resistant tumors.
Open Access PDF
Semantics
| Type | Source | Name |
|---|---|---|
| pathway | REACTOME | Ligand-receptor interactions |
| disease | MESH | melanoma |
| pathway | KEGG | Melanoma |
| disease | MESH | cancer |
| disease | MESH | neuroblastoma |
| disease | MESH | aneuploidy |
| drug | DRUGBANK | Sulpiride |
| drug | DRUGBANK | Pentaerythritol tetranitrate |
| drug | DRUGBANK | Trestolone |
| drug | DRUGBANK | Ademetionine |
| drug | DRUGBANK | Coenzyme M |